Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mustafa Erelel, Mert Kaskal, Ozlem Akbal-Dagistan, Halim Issever, Ahmet Serhan Dagistanli, Hilal Balkanci, Merve Sinem Oguz, Aygun Qarayeva, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Ali Yagiz Uresin, Ahmet Ogul Araman, Alpay Medetalibeyoglu, Tufan Tukek, Mustafa Oral Oncul, Ayca Yildiz-Pekoz
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 low-molecular-weight heparin soft-mist inhaler pulmonary anti-coagulant Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/19984ebfb6c54daa9d40a18bd3016123
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19984ebfb6c54daa9d40a18bd3016123
record_format	dspace
spelling	oai:doaj.org-article:19984ebfb6c54daa9d40a18bd30161232021-11-25T18:40:32ZEarly Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial10.3390/pharmaceutics131117681999-4923https://doaj.org/article/19984ebfb6c54daa9d40a18bd30161232021-10-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1768https://doaj.org/toc/1999-4923In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.Mustafa ErelelMert KaskalOzlem Akbal-DagistanHalim IsseverAhmet Serhan DagistanliHilal BalkanciMerve Sinem OguzAygun QarayevaMeltem CulhaAybige ErturkNur Sena BasarirGokben SahinAli Yagiz UresinAhmet Ogul AramanAlpay MedetalibeyogluTufan TukekMustafa Oral OnculAyca Yildiz-PekozMDPI AGarticleCOVID-19low-molecular-weight heparinsoft-mist inhalerpulmonaryanti-coagulantPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1768, p 1768 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 low-molecular-weight heparin soft-mist inhaler pulmonary anti-coagulant Pharmacy and materia medica RS1-441
spellingShingle	COVID-19 low-molecular-weight heparin soft-mist inhaler pulmonary anti-coagulant Pharmacy and materia medica RS1-441 Mustafa Erelel Mert Kaskal Ozlem Akbal-Dagistan Halim Issever Ahmet Serhan Dagistanli Hilal Balkanci Merve Sinem Oguz Aygun Qarayeva Meltem Culha Aybige Erturk Nur Sena Basarir Gokben Sahin Ali Yagiz Uresin Ahmet Ogul Araman Alpay Medetalibeyoglu Tufan Tukek Mustafa Oral Oncul Ayca Yildiz-Pekoz Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
description	In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.
format	article
author	Mustafa Erelel Mert Kaskal Ozlem Akbal-Dagistan Halim Issever Ahmet Serhan Dagistanli Hilal Balkanci Merve Sinem Oguz Aygun Qarayeva Meltem Culha Aybige Erturk Nur Sena Basarir Gokben Sahin Ali Yagiz Uresin Ahmet Ogul Araman Alpay Medetalibeyoglu Tufan Tukek Mustafa Oral Oncul Ayca Yildiz-Pekoz
author_facet	Mustafa Erelel Mert Kaskal Ozlem Akbal-Dagistan Halim Issever Ahmet Serhan Dagistanli Hilal Balkanci Merve Sinem Oguz Aygun Qarayeva Meltem Culha Aybige Erturk Nur Sena Basarir Gokben Sahin Ali Yagiz Uresin Ahmet Ogul Araman Alpay Medetalibeyoglu Tufan Tukek Mustafa Oral Oncul Ayca Yildiz-Pekoz
author_sort	Mustafa Erelel
title	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
title_short	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
title_full	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
title_fullStr	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
title_full_unstemmed	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
title_sort	early effects of low molecular weight heparin therapy with soft-mist inhaler for covid-19-induced hypoxemia: a phase iib trial
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/19984ebfb6c54daa9d40a18bd3016123
work_keys_str_mv	AT mustafaerelel earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT mertkaskal earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT ozlemakbaldagistan earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT halimissever earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT ahmetserhandagistanli earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT hilalbalkanci earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT mervesinemoguz earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT aygunqarayeva earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT meltemculha earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT aybigeerturk earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT nursenabasarir earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT gokbensahin earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT aliyagizuresin earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT ahmetogularaman earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT alpaymedetalibeyoglu earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT tufantukek earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT mustafaoraloncul earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial AT aycayildizpekoz earlyeffectsoflowmolecularweightheparintherapywithsoftmistinhalerforcovid19inducedhypoxemiaaphaseiibtrial
_version_	1718410819296821248

Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

Ejemplares similares